GlassScriptPhysician profile
Mansi Amin
NPI 1588196125
$3,679.36
in general payments reported to CMS, 2019-2025
22 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $53.55 · 2022: $633 · 2023: $488 · 2024: $845 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,788.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $680.70 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $520.58 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $517.46 | 2022-2025 | |
| Amgen INC. | $380.75 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $319.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $265.70 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $263.65 | 2022-2025 | |
| Lilly USA, LLC | $257.44 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $117.51 | 2023-2025 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $89.49 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.17 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.80 | 2019-2020 | |
| Corcept Therapeutics | $23.57 | 2025 | Korlym |
| Dynavax Technologies Corporation | $23.04 | 2023 | Heplisav-B |
| Grt US Holding, INC. | $22.47 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $20.70 | 2020 | |
| Abbott Laboratories | $18.27 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $17.21 | 2022 | |
| Averitas Pharma INC. | $15.72 | 2025 | Qutenza |
| Currax Pharmaceuticals LLC | $13.68 | 2024 | Contrave |
| Janssen Pharmaceuticals, INC | $12.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansi Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.